Crescent Biopharma Announces Upcoming Investor Conferences
Crescent Biopharma, Inc. (NASDAQ: CBIO) is gearing up for a series of investor presentations this November. This biotechnology company is dedicated to developing innovative treatments aimed at improving the lives of cancer patients. Their commitment to advancing new therapies is underscored by their upcoming appearances at notable investor events.
Schedule of Presentations
Guggenheim 2nd Annual Healthcare Innovation Conference
The first conference on Crescent's agenda is the Guggenheim 2nd Annual Healthcare Innovation Conference. This event is set for November 11 at 8:00 a.m. ET in Boston. During this fireside chat, the management will discuss the latest updates in their research and development pipeline.
Stifel 2025 Healthcare Conference
Following this, Crescent will present at the Stifel 2025 Healthcare Conference on November 12 at 1:20 p.m. ET in New York. This platform will allow the company to delve into the details of their innovative cancer therapies and how they plan to bring them to market.
Jefferies Global Healthcare Conference
Finally, on November 19, Crescent will participate in the Jefferies Global Healthcare Conference at 9:30 a.m. GMT (4:30 a.m. ET) in London. This global platform is a great opportunity for Crescent to engage with international investors and stakeholders.
Webcast Availability
Crescent Biopharma will provide a live webcast of each presentation, which can be accessed through the Investors section of their website. Investors and interested parties can log on to their site to stay updated on the discussions and insights that will be shared during these conferences. Additionally, a replay of the webcast will be available for a period of 90 days following the live events.
Understanding Crescent Biopharma's Vision
Crescent Biopharma is driven by a vision to lead the oncology sector, pioneering breakthrough treatments for cancer patients. Their innovative pipeline includes cutting-edge therapies such as a PD-1 x VEGF bispecific antibody along with other unique antibody-drug conjugates (ADCs). The company's approach is multi-faceted; they are committed to leveraging established research and novel mechanisms to design potentially transformative treatments. This includes developing therapies that can be used independently or in conjunction with existing treatments to enhance efficacy against a wide variety of solid tumors.
Company Contact Information
For those interested in learning more about Crescent Biopharma, they encourage visits to their official website. The company thrives on engagement with the broader community and is happy to field inquiries. The Chief Communications Officer, Amy Reilly, is the designated contact for communications regarding the company's strategies and upcoming plans. She can be reached via email or by phone for any pressing questions.
Frequently Asked Questions
What is Crescent Biopharma's focus?
Crescent Biopharma focuses on developing innovative therapies for cancer patients, aiming to bring advanced treatments to the market.
When are the investor conferences taking place?
The conferences are scheduled for November 11, 12, and 19, 2025.
How can I access the live presentations?
The live presentations will be available on the Investors section of Crescent's website, with replays accessible for 90 days.
What types of therapies is Crescent working on?
Crescent’s pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates.
Who can I contact for more information?
Amy Reilly, the Chief Communications Officer, can be contacted via email or phone for further inquiries regarding the company's advancements.
